Supplementary Information
thrombosis, fatigue, IVH, PNH, hemolysis
THROMBOSIS, HEMOLYSIS, PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH), PNH
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by uncontrolled terminal complement activation leading to intravascular hemolysis (IVH), thrombosis, and impairments in quality of life (QoL). The aim of this study was to identify the clinical drivers of improvement in patient-reported outcomes (PROs) in patients with PNH receiving the complement component 5 (C5) inhibitors eculizumab and ravulizumab.This Improvements in absolute mean LDH levels were significantly associated with improvements in mean FACIT-F score (These findings suggest that LDH levels are an important determinant of fatigue and QoL outcomes in patients with PNH. The online version contains supplementary material available at 10.1007/s00277-023-05483-0.